

The Value of Urinary Neutrophil Gelatinase-Associated Lipocalin in the Differential Diagnosis of Acute Kidney Injury in Liver Cirrhosis

Thesis

Submitted For Partial Fulfillment of Master Degree
In Tropical Medicine

By

Mohammad Abdel-Monem Lasheen

(M.B., B.Ch)

Under Supervision of

Prof. Hassan Salah-Eldeen Hamdy, MD

Professor of Tropical Medicine
Faculty of Medicine, Ain Shams University

Prof. Ahmed Aly El-Ray, MD

Professor of Tropical Medicine
Theodor Bilharz Research Institute

Dr. Mohamed Salaheldin Khalaf, MD

Lecturer of Tropical Medicine
Faculty of Medicine, Ain Shams University

**Faculty of Medicine
Ain Shams University**

2016

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

سبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Key words: Acute kidney injury, prerenal, FENa, Neutrophil gelatinase associated lipocalin, acute tubular necrosis, HRS, ascites, liver cirrhosis

Abstract:

Introduction of acute kidney injury was mentioned. Types of AKI in liver cirrhosis was listed. Urinary NGAL and its measurement importance was discussed. Concerning diagnostic performance of uNGAL in differentiating the different types of AKI, uNGAL has good diagnostic performance in the differentiation, uNGAL levels were significantly different in each category of AKI: highest in iAKI, intermediate in HRS and low in prerenal disease. Furthermore, uNGAL levels in patients with prerenal azotemia were similar to those with normal kidney function.

Urinary NGAL has not only potentiality to detect AKI but also has the ability to differentiate cause of AKI as shown in the current study that revealed uNGAL > 30 ng/mg, 15-39 ng/mg, 39-143 ng/mg and >143 ng/mg had the highest characteristics as a diagnostic marker for detecting AKI, diagnosis of prerenal group, HRS and ATN patients respectively.



Acknowledgments

*First and foremost, praise and thanks must be to **ALLAH**, Who guides me throughout life.*

*I would like to express my deepest gratitude and thanks to **Prof. Hassan Salah-Eldeen Hamdy**, Professor of Tropical Medicine, Faculty of Medicine, Ain Shams University for his kind continuous encouragement and great support throughout the work. It was a great honor to be a student working under his supervision.*

*I am also greatly indebted and grateful to **Prof. Ahmed Aly El-Raay**, Professor of Hepatology and Gastroenterology, Theodor Bilharz Research Institute, for his great help, valuable time, careful supervision and continuous advices and his efforts that made this work come to light.*

*I am also greatly indebted to **Dr. Mohamed Salaheldin Khalaf**, Lecturer of Tropical Medicine, Faculty of Medicine, Ain Shams University, it was impossible for me to finish this work without his wise instructions and guidance. No words would ever fulfill my deepest gratitude towards his support.*

*Also I am really deeply grateful to **Dr. Mohammed Abu El-ezz**, Lecturer of Hepatology and Gastroenterology, Theodor Bilharz Research Institute, for his careful and great support.*

*I am really thankful to **Prof. Dr. Iris Gerges**, Professor of Clinical Pathology, Theodor Bilharz Research Institute who took part in exhibiting this work to light.*

*Last but not least, I can't forget to thank my **Parents**, for pushing me forward in every step of my life.*

Candidate



Mohammad Abdel-Monem Lasheen

List of Contents

<i>Subject</i>	<i>Page No.</i>
List of Abbreviations.....	i
List of Tables.....	iii
List of Figures	vi
Introduction	1
Aim of the Work.....	5
Review of Literature	
Hemodynamics in Cirrhosis.....	6
Acute Kidney Injury in Liver Cirrhosis	22
Human Neutrophil Gelatinase Associate Lipocalin (NGAL)	43
Patients and Methods.....	59
Results.....	64
Discussion	95
Conclusion.....	105
Recommendations	106
Summary	107
References	112
Arabic Summary	—

List of Abbreviations

Abbr.	Full-term
AKI	: Acute kidney injury
AKIN	: Acute kidney injury network
ATN	: Acute tubular necrosis
CB1	: Cannabinoid 1
CKD	: Chronic kidney disease
CSPH	: Clinically significant portal hypertension
eNOS	: Endothelial NO synthase
ET-1	: Endothelin-1
FENa	: Fractional excretion of sodium
FGF	: Fibroblast growth factor
GFR	: Glomerular filtration rate
HRS	: Hepatorenal syndrome
HSCs	: Hepatic stellate cells
HVPG	: Hepatic venous pressure gradient
ICA	: International club of ascites
KDIGO	: Kidney disease improving global outcome
Lcn2	: Lipocalin 2
MAP	: Mean arterial pressure
MDRD	: Modification of Diet in Renal Disease
MELD	: Model of end stage liver disease
MMP-9	: Matrix metalloproteinase-9

NGAL	: Neutrophil-gelatinase-associated lipocalin
NO	: Nitric oxide
NSAIDs	: Non-steroidal anti-inflammatory drugs
PDGF	: Platelet-derived growth factor
PGE	: Prostaglandin E
RAAS	: Renin-angiotensin-aldosterone system
SARS	: Severe acute respiratory syndrome
SBP	: Spontaneous bacterial peritonitis
sCr	: Serum creatinine
SECs	: Sinusoidal endothelial cells
sGC	: Soluble guanylyl cyclase
TGF-β1	: Transforming growth factor-beta 1
VEGF	: Vascular endothelial growth factor

List of Tables

Table No.	Title	Page No.
Table (1):	Hemodynamic changes in different vascular beds in Cirrhosis.....	21
Table (2):	Current diagnostic criteria for acute kidney injury (AKI) in the general population and in patients with cirrhosis.....	27
Table (3):	International Club of Ascites (ICA-AKI) new definitions for the diagnosis and management of AKI in patients with cirrhosis.....	31
Table (4):	Desirable characteristics of acute kidney injury biomarkers.....	55
Table (5):	Expression of NGAL in benign conditions	56
Table (6):	Expression of NGAL in malignant conditions	57
Table (7):	Demographic data.....	64
Table (8):	Clinical data.....	65
Table (9):	Pelvi-abdominal ultrasound findings.....	65
Table (10):	Laboratory investigations.....	66
Table (11):	Urinary NAGAL (ng/mg).....	66
Table (12):	Outcome.....	68
Table (13):	Diagnosis.....	68
Table (14):	Comparison between prerenal AKI, HRS and ATN as regard demographic data.....	68

Table (15): Comparison between prerenal AKI, HRS and ATN as regard clinical data.	69
Table (16): Comparison between prerenal AKI, HRS and ATN as regard pelvi-abdominal ultrasound findings.	70
Table (17): Comparison between prerenal AKI, HRS and ATN as regard complete blood picture.....	70
Table (18): Comparison between prerenal AKI, HRS and ATN as regard liver function test.	71
Table (19): Comparison between prerenal AKI, HRS and ATN as regard kidney function test.....	72
Table (20): Comparison between prerenal AKI, HRS and ATN as regard Urinary NAGAL (ng/mg).....	75
Table (21): Comparison between prerenal AKI, HRS and ATN as regard Urinary NAGAL (ng/mg).....	76
Table (22): Comparison between prerenal AKI, HRS and ATN as regard outcome	77
Table (23): Correlation between Urinary NAGAL (ng/mg) and study parameters.	78
Table (24): Relation between Urinary NAGAL (ng/mg) and demographic/clinical data.	82
Table (25): Validity of Urinary NAGAL (ng/mg) as diagnostic marker for acute kidney injury (vs control) in cirrhotic patients; ROC curve analysis.....	85
Table (26): Validity of Urinary NAGAL (ng/mg) as diagnostic marker for HRS (vs prerenal AKI) in cirrhotic patients; ROC curve analysis	86

Table (27): Validity of Urinary NAGAL (ng/mg) as diagnostic marker for ATN (vs prerenal AKI) in cirrhotic patients; ROC curve analysis.....	87
Table (28): Validity of Urinary NAGAL (ng/mg) as diagnostic marker for ATN (vs HRS) in cirrhotic patients; ROC curve analysis	88
Table (29): Summary of Urinary NAGAL (ng/mg) as diagnostic marker for AKI in cirrhotic patients.....	89
Table (30): Comparison between alive and died cirrhotic patients with AKI as regard Urinary NAGAL (ng/mg) and MELD.....	89
Table (31): Validity of Urinary NAGAL (ng/mg) and MELD as predictor marker for mortality in cirrhotic patients with AKI; ROC curve analysis.....	91
Table (32): Univariate logistic regression of potential predictors of mortality in cirrhotic patients with AKI.....	92
Table (33): Multivariate logistic regression of potential predictors of mortality in cirrhotic patients with AKI.....	92

List of Figures

Figure No.	Title	Page No.
Figure (1):	Anatomy of the splanchnic, portal and hepatic venous circulation	9
Figure (2):	Hepatic stellate cell (HSC) activation	10
Figure (3):	Pathogenesis of hyperdynamic circulation in cirrhosis and portal hypertension	15
Figure (4):	Proposed algorithm for the management of acute kidney injury (AKI) according to International Club of Ascites—AKI (ICA-AKI) classification.....	34
Figure (5):	Extra-renal influences on serum creatinine levels.....	37
Figure (6):	Precipitants, mechanisms and clinical correlates of hepatorenal syndrome and acute tubular necrosis in cirrhosis	38
Figure (7):	Diagnostic considerations for acute kidney injury (AKI) and the hepatorenal syndrome (HRS) and evidence-based treatment options	42
Figure (8):	Schematic of neutrophil gelatinase-associated lipocalin (NGAL) cellular turnover.....	48
Figure (9):	Mechanism of bacteriostatic action of NGAL	50
Figure (10):	The cellular role of neutrophil gelatinase-associated lipocalin may be dependent on the type of molecule it is complexed with.....	55

Figure (11): Box-plot shows comparison between cirrhotic patients without AKI and cirrhotic patients with AKI as regard Urinary NAGAL	67
Figure (12): Box-plot shows comparison between prerenal AKI, HRS and ATN as regard serum creatinine.....	73
Figure (13): Box-plot shows comparison between prerenal AKI, HRS and ATN as regard eGFR.....	73
Figure (14): Box-plot shows comparison between prerenal AKI, HRS and ATN as regard serum Na.....	74
Figure (15): Box-plot shows comparison between prerenal AKI, HRS and ATN as regard urinary Na	74
Figure (16): Box-plot shows comparison between prerenal AKI, HRS and ATN as regard FeNa	75
Figure (17): Box-plot shows comparison between prerenal AKI, HRS and ATN as regard uNAGAL	76
Figure (18): Kaplan-Meier plot shows Overall survival stratified according to kidney function groups.	77
Figure (19): Scatter plot with regression line shows correlation between AST (U/L) and Urinary NAGAL (ng/mg).	79
Figure (20): Scatter plot with regression line shows correlation between ALT (U/L) and Urinary NAGAL (ng/mg).	79

Figure (21): Scatter plot with regression line shows correlation between serum creatinine (mg/dl) and Urinary NAGAL (ng/mg).....	80
Figure (22): Scatter plot with regression line shows correlation between eGFR (ml/min/1.73m ²) and Urinary NAGAL (ng/mg).....	80
Figure (23): Scatter plot with regression line shows correlation between FeNa(%) and Urinary NAGAL (ng/mg).	81
Figure (24): Scatter plot with regression line shows correlation between length of hospital stay (days) and Urinary NAGAL (ng/mg).....	81
Figure (25): Box-plot shows relation between Urinary NAGAL (ng/mg) and serum creatinine.....	83
Figure (26): Box-plot shows relation between Urinary NAGAL (ng/mg) and eGFR.....	83
Figure (27): Box-plot shows relation between Urinary NAGAL (ng/mg) and urinary Na	84
Figure (28): Box-plot shows relation between Urinary NAGAL (ng/mg) and FeNa.....	84
Figure (29): Receiver operating characteristic (ROC) curve of Urinary NAGAL (ng/mg) as diagnostic marker for acute kidney injury (vs control) in cirrhotic patients.	85
Figure (30): Receiver operating characteristic (ROC) curve of Urinary NAGAL (ng/mg) as diagnostic marker for HRS (vs prerenal AKI) in cirrhotic patients.....	86

Figure (31): Receiver operating characteristic (ROC) curve of Urinary NAGAL (ng/mg) as diagnostic marker for ATN (vs prerenal AKI) in cirrhotic patients.....	87
Figure (32): Receiver operating characteristic (ROC) curve of Urinary NAGAL (ng/mg) as diagnostic marker for ATN (vs HRS) in cirrhotic patients.	88
Figure (33): Box-plot shows comparison between alive and died cirrhotic patients with AKI as regard Urinary NAGAL (ng/mg).....	90
Figure (34): Box-plot shows comparison between alive and died cirrhotic patients with AKI as regard MELD.....	90
Figure (35): Receiver operating characteristic (ROC) curve of Urinary NAGAL (ng/mg) and MELD as predictor marker for mortality in cirrhotic patients with AKI.....	91
Figure (36): Multivariate logistic regression of potential predictors of mortality in cirrhotic patients with AKI.....	94

Introduction

Physicians caring for patients with cirrhosis should recognize the acute or chronic character of renal disease; the causes of renal injury; the clinical conditions leading concomitantly to acute kidney injury (AKI) and liver dysfunction, and the prognostic factors associated with the progression of AKI. Hypovolemia (due to diuretics, hemorrhage, diarrhea), acute tubular necrosis, sepsis, nephrotoxic agents (such as non steroidal anti-inflammatory drugs, aminoglycosides radiological contrasts) and hepatorenal syndrome-type 1 are the most common causes of AKI in cirrhotic patients (*Hartleb and Gutkowski, 2012*).

Acute kidney injury (AKI) in patients with cirrhosis is common and deadly. Up to 20% of hospitalized patients with cirrhosis develop AKI and once AKI occurs, there is a reported fourfold increased risk of mortality (*Du Cheyronnet al., 2005*).

In cirrhosis, AKI types include prerenal azotemia, hepatorenal syndrome (HRS), and acute tubular necrosis (ATN) (*Garcia-Tsao et al., 2008*).

Unfortunately these forms of AKI are difficult to be distinguished clinically as serum creatinine (sCr), the clinical